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once-a-day. Such lower peak plasma concentrations might not
reach the pharmacologically effective threshold and could ex-
plain the lack of efﬁcacy of glucosamine hydrochloride observed
in GAIT compared to the GUIDE and previous long-term trials of
crystalline glucosamine sulfate. Combination of glucosamine hy-
drochloride with chondroitin sulfate further reduces glucosamine
bioavailability.
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Purpose: While systemic administration of interleukin-1 (IL-1)
receptor antagonist (IL1Ra) is approved for treating RA, a high
incidence of side effects and need for frequent dosing does
not suggest utility for treating OA. Local delivery of an IL1Ra-
containing drug depot could provide for sustained drug presence,
decreased dosing requirements, and reduce systemic toxicity for
OA. Elastin-like polypeptides (ELPs) have been developed as
injectable, and thermally-responsive intra-articular drug depots.
ELPs had a joint space half-life 25-fold greater than that of
comparable non-responsive proteins. Here we evaluate the ac-
tivity of an intra-articular injection of IL1Ra conjugated to ELP in
attenuating IL-1β induced pathology in a rat knee joint model.
Methods:A fusion protein of human IL1Ra and ELP (ELP-IL1Ra)
was synthesized as described previously. Right knee joints of 18
rats were injected with 12,500 rat dermal ﬁbroblasts modiﬁed to
over-express human IL-1β. After 24h, 6 rats each received one of
the following injections: ELP-IL1Ra fusion protein (120µg), com-
mercial IL1Ra (0.24µg), or no treatment. Protein doses insured
that IC50 values were equal for fusion and commercial IL1Ra.
Daily weights, coronal and sagittal knee joint diameters were
recorded. After 7 days, rats were sacriﬁced and right knees eval-
uated for grade of gross pathology (0-2, 0 = non-degenerate).
Joints were placed in explant culture for 24h and human and
rat IL-1β expression was measured in supernatants via ELISA.
Joint sections were evaluated for histological evidence of OA
(OARSI Histopathology Assessment; 0-6, 0 = non-degenerate).
All data are reported relative to contralateral controls. Chi-square
analysis was performed on gross and OARSI grades; one-way
ANOVA was performed on body weights, knee joint diameters,
and ELISA data. Bonferroni post-hoc analyses were used.
Results: There was no difference in body weight gain, or coronal
or sagittal knee joint diameters amongst groups. Gross pathology
was different amongst groups (p<0.04, Chi-square, Table). The
ELP-IL1Ra group had less pathology than no treatment animals
(p<0.01, Figure 1). OARSI grades were signiﬁcantly lower for
Figure 1. Images of ﬁbroblast injected knee joints receiving no treatment (a),
commercial IL-1Ra (b), or the ELP-IL1Ra fusion protein (c).
Table 1. Grades relative to contralateral control
Gross grades OARSI grades
Femoral Femoral Tibial
groove condyle plateau
ELP-IL1Ra 0.17±0.93* 2.8±2.2* -0.17±1.6* -0.83±1.8
Commercial rhIL1Ra 1.1±0.74 4.6±2.6 2.2±2.4 4.0±2.0
No treatment 1.7±0.3 4.3±3.1 5.5±0.84 1.5±2.5
*Signiﬁcant difference from no treatment group, Bonferroni post-hoc test.
the ELP-IL1Ra group at patellofemoral (p<0.006) and condylar
sites (p<0.015), but not tibial plateau, compared to no treatment
animals (Table 1). There was no statistical difference between
commercial IL1Ra and either no treatment or ELP-IL1Ra groups
in gross pathology or OARSI grades. There was no difference
in amount of human or rat IL-1β in explant cultures indicating
that all groups had the same potential to develop pathological
changes.
Conclusions: These data show efﬁcacy for the ELP-IL1Ra fu-
sion protein in mediating effects of IL-1β induced knee pathology.
Single intra-articular administration of the fusion protein ELP-
IL1Ra has the potential for release of an active IL1Ra domain
for up to 4 weeks in the rat model, and may have potential to
provide therapeutic effects when delivered locally in patients with
OA.
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Purpose: In osteoarthritis (OA) pain, and not the structural
changes in the joint, are the main reason for a patient to seek
medical attention. The exact origin of joint pain in OA is hardly
known, but undoubtedly pain is related to the secondary inﬂam-
matory responses in OA. This inﬂammation contributes to joint
damage and therefore, by diminishing inﬂammation pain will be
diminished and development of OA will be slowed down. NSAIDs
and COXIBs might be useful in this respect, although with re-
strictions. Therefore, the need remains for alternatives, of which
many presently under investigation. Glycine might be a novel
candidate in this respect. Glycine as a single molecule has anti-
inﬂammatory capacities; amongst others, dietary glycine showed
an inhibitory effect on the development of arthritis (Li X, e al.
Infect Immun 2001; 69: 5883-). In the present study glycine was
evaluated as a dietary supplement on the development of OA.
For this purpose we choose an experimental canine OA model
with moderate but clearly evident synovial inﬂammatory activity;
the ACLT model combined with medial meniscectomy (Mx).
Methods:Knee osteoarthritis (OA) was induced in dogs by ACLT-
Mx (n=12). Double blind, either glycine (10g/dog) or placebo was
given orally daily, every morning at the same time before the
meal was given. Longitudinal as well as endpoint parameters of
cartilage damage, synovial inﬂammation and pain were evalu-
ated.
Results: Twelve weeks post-surgery OA characteristics were
clearly present; radiographs revealed progressive osteophyte
formation in the experimental joints (p<0.05). Gait analysis re-
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vealed, a decrease in peak ground reaction forces of the ex-
perimental leg related to the course of OA (p<0.05). This was
supported by the structural end point measurements. Cartilage
integrity was damaged as reﬂected by an increased macroscopic
( +2.2) and histological score ( +2.0), and by a decreased
proteoglycan content (-20%; all p<0.05). Chondrocyte activity
demonstrated an increase in proteoglycan synthesis rate (+73%)
and release (+64%; both p<0.05). Furthermore, synovial inﬂam-
mation was present macroscopically ( +3.5), and histologically
( +2.0; both p<0.05). This was corroborated by increased syn-
ovial ﬂuid whit blood cell count (WBCC  +1.5) and NO levels
(+30%) increasing during the course of OA.
In the treatment group glycine uptake could be demonstrated:
glycine was found in sufﬁcient amounts in serum and synovial
ﬂuid over time (all time points p<0.05). However, as a result
of treatment no changes in cartilage parameters, osteophyte
formation, and gait were observed. Also, no changes in end stage
inﬂammation and synovial ﬂuid MMP activity were observed.
However, synovial ﬂuid WBCC, and NO production were slightly,
temporarily, but statistically signiﬁcantly (p<0.05) decreased in
the glycine treatment group compared to the placebo group
during the course of OA development.
Conclusions: Glycine, as a potential anti-inﬂammatory agent,
is absorbed by the gastro intestinal tract and reaches serum
and synovial ﬂuid, leading to minor temporary changes in joint
inﬂammation which are not reﬂected by structural and clinical
relevant changes during development of experimentally induced
osteoarthritis in de ACLT-Mx model.
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Purpose: Although topical NSAIDs have been used for many
years, additional supporting evidence of their value is needed.
This study was conducted to determine the efﬁcacy and safety
of topical diclofenac sodium gel 1% (DSG) in knee osteoarthritis
(KOA).
Methods: Patients in this double-blind, randomized, parallel-
group, multicenter 12-week trial had a history of primary KOA
(meeting American College of Rheumatology [ACR] criteria),
diagnosed at least 6 months prior to study entry and symptomatic
in only 1 knee. Patients were randomized to DSG (n=254) or
vehicle (n=238), applied as 4 g to the signal knee 4 times daily.
After a 7-day washout from previous pain medication, baseline
pain on movement was at least 50 mm on a 100-mm visual
analog scale (VAS), and the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) pain subscale was at
least 9 (out of 20; Likert scale v 3.1). Acetaminophen up to 4
g per day was permitted as rescue medication throughout the
study. Primary efﬁcacy variables at Week 12 included WOMAC
pain subscale (scale = 0 to 20), WOMAC function subscale
(scale = 0 to 68), and global rating of disease (100 mm VAS).
Secondary outcome variables included efﬁcacy at other time
points of the study, success rates based on the Osteoarthritis
Research Society International (OARSI) response criteria, and
use of rescue medication. Safety was assessed at all time points.
Results: Disposition: 77% completed the study. Demographics:
women 2:1 men; 75% white; mean age 60 years (2/3 between
50 and 70); mean pain on movement 71 mm by VAS; mean
WOMAC pain 12. Prior to unblinding, the protocol was amended
to exclude from the efﬁcacy analysis patients with signiﬁcant pain
at baseline in the contralateral knee and/or a decrease in pain on
Table 1. WOMAC pain, WOMAC physical function, and global rating of disease
at Week 12
DSG (n=127) Vehicle (n=119) P-value
WOMAC pain
Mean 5.62 7.38 0.023
Mean  from baseline 5.85 4.68
WOMAC physical function
Mean 19.67 25.72 0.003
Mean  from baseline 17.50 11.80
Patient global
Mean 31.6 41.5 0.018
Mean  from baseline 30.0 22.4
DSG = diclofenac sodium gel 1%; WOMAC = Western Ontario and McMaster
Universities Osteoarthritis Index.
movement over the washout from the screening to the baseline
visit. Table 1 shows the results in the primary efﬁcacy variables
at Week 12. On all important secondary endpoints, patients on
active treatment had a signiﬁcantly better outcome than patients
randomized to vehicle. Table 2 shows response rates based on
the OARSI success criteria.
Table 2. OARSI response, WOMAC pain index normalized to 100-pt scale
OARSI response rate, n (%) DSG, (n=127) Vehicle, (n=119) P-value
Week 1 87 (68.5) 59 (49.6) 0.005
Week 4 94 (74.0) 72 (60.5) 0.043
Week 8 95 (74.8) 70 (58.8) 0.013
Week 12 94 (74.0) 70 (58.8) 0.024
DSG = diclofenac sodium gel 1%; WOMAC = Western Ontario and McMaster
Universities Osteoarthritis index; OARSI = Osteoarthritis Research Society In-
ternational.
The mean number of weeks with no rescue medication use was
signiﬁcantly greater in the DSG group (4.7 weeks) compared
with the vehicle group (3.1 weeks, P=.004).
Adverse events overall were slightly more frequent in the DSG
group than in the vehicle group (60.2% vs 53.8%) with most AEs
being mild or moderate in severity. The incidence of mild gas-
trointestinal disorders was low and comparable in both treatment
groups (DSG: 5.9%, vehicle: 5.0%). Incidence of application site
dermatitis was higher in the DSG group: 4.3% compared with
1.7% in the vehicle group. However, discontinuation rates due to
application site conditions were low in both groups (DSG: 2.0%,
vehicle: 0.8%). Rates of discontinuation of treatment due to AEs
overall were slightly higher in the active treatment group (DSG:
5.1%, vehicle: 3.8%).
Conclusions: In a double-blind, controlled trial, topical diclofenac
sodium gel 1% was superior to vehicle in reducing pain, improv-
ing physical function, and patient global rating of disease for
KOA. DSG was well tolerated.
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Purpose: The sequence of AC-100 is derived from a central 23-
amino acid region of MEPE - an extracellular matrix protein and
is one of the more conserved regions of the molecule. AC-100
has shown speciﬁc activity in vivo to promote tissue appropriate
hard tissue deposition in teeth and in bone. Cell culture studies
have shown AC-100 has potent anabolic activity on osteoblast
and odontoblast precursor cells in vitro. Local PGE2 production
